Legislation Prevents Drugmaker Anticompetitive Behavior
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Fair Access for Safe and Timely (“FAST”) Generics Act, introduced today by Reps. David McKinley (R-WV) and Peter Welch (D-VT).
“This legislation will help bring generics to market faster, which is the key to reducing drug costs,” said PCMA President and CEO Mark Merritt.
The bipartisan legislation prevents brand drug manufacturer abuses of risk evaluation and mitigation strategies (REMS) that block generic competition. Allowing generic and biosimilar drugs to get to market more quickly will reduce overall drug costs.
PCMA is joined by a broad group of stakeholders in support of the legislation, including the Association for Accessible Medicines, the Academy of Managed Care Pharmacy, Public Citizen, and the Blue Cross Blue Shield Association.